Clinical Trials
27 trialsNCT03528642 2026-05-13
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05765812 2026-04-28
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT07015242 2026-03-24
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT06475235 2026-02-20
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT01139970 2025-11-20
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT07215910 2025-10-14
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Not yet recruiting
NCT03495960 2025-01-30
FIORELLA
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT03323034 2024-10-22
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT01618136 2023-06-18
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT04514393 2022-04-07
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT02590263 2020-09-03
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
AbbVie
Phase 1/2 Completed
NCT01235793 2018-11-20
DRBEAT
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT00248534 2018-09-04
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00068250 2018-02-07
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00109798 2017-09-19
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
The Methodist Hospital Research Institute
Phase NA Withdrawn
NCT02113007 2017-02-07
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00098774 2016-07-06
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00416819 2015-08-20
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
University of California, San Francisco
Phase NA Completed
NCT00083070 2014-02-20
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
Children's Oncology Group
Phase 1 Completed
NCT01985451 2013-11-15
Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT00098436 2013-07-18
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
National Cancer Institute (NCI)
Phase 1 Completed
NCT01735747 2013-03-12
Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT00544284 2013-02-15
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Phase 1 Completed
NCT00503594 2012-07-30
CNSLymphoma
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT00004106 2012-06-06
Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Northwestern University
Phase 2 Terminated
NCT00003567 2010-06-11
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated